when was semaglutide fda approved U.S. | The FDA has a new higher dose (7.2 mg) of Wegovy ( semaglutide) injection, Wegovy HD, for weight loss and long-term weight High-Dose Wegovy Wins FDA Approval

Fasting helps manage eating patterns and supports metabolic health, while semaglutide controls appetite and improves insulin sensitivity

Mounjaro (Tirzepatide) Dual action: targets both GLP-1 and GIP receptors Strong appetite suppression & improved blood sugar control Clinical trials show average body weight loss up to 22.5% over 72 weeks Wegovy (Semaglutide) Targets GLP-1 receptors only Licensed in the UK for obesity and cardiovascular protection STEP trials show 1521% body weight loss A new 7.2mg dose is expected in late 2025, with results potentially matching Mounjaro Both treatments are once-weekly injections, prescribed alongside healthy diet and lifestyle changes

Kerr-German would like to see more research, especially in how external factors, such as pathogens or material pollution, can impact the brain of a developing fetus

Control et al., 1993

Formulary decisions can be made on clinical and net-cost grounds without a competing revenue motive